Akebia Therapeutics Inc. Logo

Akebia Therapeutics Inc. (AX9)

FSX

Currency in EUR
0.4944
-0.01 (-2.72%)

Delayed Data

Oct 23, 2026, 06:00 AM

Day's Range

0.4944
0.4944

52 wk Range

0.4944
2.76

Overview - AX9 - Akebia Therapeutics Inc.

Key Statistics

Valuation

Enterprise Value

227.11M

P/E (Trailing)

‪-34.97‬

P/E (Forward)

‪-0.89‬

Price / Sales (TTM)

‪0.88‬

Price / Book

‪8.51‬

EV / EBITDA

‪-59.22‬

Profitability

Gross Margin

‪78.78%‬

Profit Margin

‪-13.54%‬

Operating Margin

‪-5.45%‬

Return on Assets

‪-1.05%‬

Return on Equity

‪-109.38%‬

Ownership

Shares Outstanding

271.74M

Float

272.25M

Held by Insiders

‪1.98%‬

Held by Institutions

‪40.77%‬

Price stats

Beta

‪0.18‬

50-Day Avg

‪0.7988‬

200-Day Avg

‪1.01‬

Latest News - AX9 - Akebia Therapeutics Inc.

News & Analysis

View all news

Market Cap - AX9 - Akebia Therapeutics Inc.

Peers - AX9 - Akebia Therapeutics Inc.

Peer Comparison

Compared with companies in Drug Manufacturers - Specialty & Generic listed on FSX.

Profile Summary - AX9 - Akebia Therapeutics Inc.

About

Akebia Therapeutics Inc. is a biopharmaceutical company focused on developing and commercializing therapies for people living with kidney disease. Its current product portfolio centers on treatments for chronic kidney disease-related complications, including anemia management and phosphorus control, supported by a…

SectorHealthcare
IndustryDrug Manufacturers - Specialty & Generic
Employees194
Full company profile

The information on this page is provided for general informational purposes only and is not investment advice.

Market data provided by Twelve Data. Charting by TradingView.

Last updated:

Track Global Markets in Real Time with UA Finance

Download the app now and access live financial data, expert analysis, and trusted economic news to follow stocks, forex, gold, and cryptocurrencies with ease.